Not Losing Weight on Mounjaro? Here's Why — and What Can Change

Step 1: Understand what a plateau actually means on tirzepatide

A weight-loss plateau is not a sign that Mounjaro has stopped working. It is a well-recognised phase of treatment, and it shows up in the clinical trial data too. In SURMOUNT-1, the large phase-3 trial published in the New England Journal of Medicine, the rate of weight loss was steepest in the first months and then slowed, but participants who stayed on the highest tolerated dose continued to lose weight over 72 weeks, reaching average reductions of around 20–21% of body weight at 15mg. The body is not a calculator. As you lose weight, your resting energy needs fall, your metabolism adapts, and the same calorie deficit produces a smaller deficit in practice. None of that is a failure of the medicine.

There is also a common misconception worth letting go of gently: that a week or two without the scale moving means the treatment is no longer active. Mounjaro continues to signal satiety and slow gastric emptying whether the number on the scales moves that week or not. Short-term plateaus (two to four weeks) are almost always part of the normal pattern rather than a sign that something is wrong.

The mechanism behind tirzepatide's weight-loss effect explains why the early response is often the most dramatic: the appetite suppression is novel and pronounced at first, and the body has not yet adapted. Adaptation is not resistance.

Step 2: Check whether dose, duration or consistency is the variable

Tirzepatide works on a titration schedule, treatment starts at 2.5mg, a dose whose job is to let your system adjust, and moves upward in steps guided by the prescriber. If you are not losing weight on a lower dose, the clinical question is whether you have reached your optimal maintenance dose yet. Many people see the most significant results at 10mg or 15mg, not at the starting strength.

Duration matters too. NICE's appraisal of tirzepatide (TA1026) notes that if less than 5% weight loss has occurred after six months at the highest tolerated dose, continuing treatment should be reviewed. Six months at the highest tolerated dose, not six months from the first injection. That distinction matters when assessing whether treatment is working.

Consistency is a quieter factor. Missing doses, especially multiple in a row, affects how steadily tirzepatide does its job. If you have had stretches of inconsistent use, that may explain a stall more than the medicine itself. The practical guide to getting results on Mounjaro covers the lifestyle factors that support the medicine, protein adequacy, staying hydrated and keeping up with activity all interact with how effectively tirzepatide reduces appetite and preserves muscle mass. Some people also ask whether combining supplements with their treatment could help, and if that question applies to you, it is worth reading about taking l carnitine and tirzepatide together before making any changes.

Step 3: Look at what is happening around the medicine

Tirzepatide is licensed alongside a reduced-calorie diet and increased physical activity, not instead of them. The trial results that underpin the licence (including those cited by NICE in TA1026) were produced in participants following structured lifestyle programmes. In practice, the medicine often makes those changes feel manageable in a way they did not before. But if calorie intake has gradually crept back up, if portions have drifted, or if activity has fallen since the early weeks, the medicine has less to work with.

Sleep, stress and certain medicines can all affect weight independently of tirzepatide. Corticosteroids, some antidepressants and other medicines can blunt weight-loss responses. A prescriber reviewing your progress is the right person to assess whether something in that picture is worth exploring. This is not about blame; it is about finding the variable that is limiting a medicine that, in clinical trials, produced some of the most substantial average weight reductions seen in this class.

If you are wondering whether the cost of staying on treatment makes sense when progress has slowed, the context around Mounjaro pricing in the UK is worth understanding before making a decision. Price is a legitimate consideration, but stopping a medicine because of a temporary plateau often means restarting later, at cost, and with the re-introduction phase to navigate again.

Step 4: When to ask for a clinical review rather than stopping

If weight loss has stalled for more than four to six weeks and you have been consistent with your dose, the right move is a conversation with your prescriber, not stopping independently. A prescriber can assess whether a dose increase is appropriate, whether something in your health picture has changed, or whether the stall reflects the medicine reaching a new set point that might shift with time or a different approach.

Stopping Mounjaro abruptly without clinical guidance is associated with weight returning. The appetite-suppressing effect is tied to the medicine being present in the body; it is not a permanent reset. The NHS notes this clearly for GLP-1 medicines, the effect is ongoing, not curative.

At nume, every repeat order is reviewed by a GPhC-registered prescriber before it is dispensed. If your progress has stalled and you want a clinical perspective on why, our clinical team is available. You can also explore what the evidence says about individual variation in response to tirzepatide before you decide. When you are ready to discuss your options, starting a free consultation puts your case in front of a prescriber the same day.